Patients and studies
| . | Patients . | No events . | Relapse . | Died before first HDMTX . | Change of protocol before first HDMTX . | SMN . | Dead in CR . |
|---|---|---|---|---|---|---|---|
| All patients | 563 | 452 | 74 | 22 | 5 | 5 | 5 |
| All patients treated at Rigshospitalet | 238 | 192 | 31 | 6 | 3 | 3 | 3 |
| Outcome study | 500 | 422 | 70 | 0 | 0 | 5 | 3 |
| Toxicity study, first HDM course | 123 | 110 | 15 | 1 | |||
| Toxicity study, all HDM courses | 182 | 156 | 22 | 2 | 2 |
| . | Patients . | No events . | Relapse . | Died before first HDMTX . | Change of protocol before first HDMTX . | SMN . | Dead in CR . |
|---|---|---|---|---|---|---|---|
| All patients | 563 | 452 | 74 | 22 | 5 | 5 | 5 |
| All patients treated at Rigshospitalet | 238 | 192 | 31 | 6 | 3 | 3 | 3 |
| Outcome study | 500 | 422 | 70 | 0 | 0 | 5 | 3 |
| Toxicity study, first HDM course | 123 | 110 | 15 | 1 | |||
| Toxicity study, all HDM courses | 182 | 156 | 22 | 2 | 2 |
HDMTX indicates high-dose methotrexate; SMN, secondary malignancy; and CR, complete remission.